|Ms. Saundra Pelletier||Interim Chair, Pres & CEO||1.23M||N/A||1970|
|Mr. Justin J. File||Chief Financial Officer||809.24k||N/A||1970|
|Mr. Alexander A. Fitzpatrick Esq.||Exec. VP, Gen. Counsel & Sec.||594.2k||N/A||1967|
|Ms. Amy Raskopf||VP of Investor Relations||N/A||N/A||N/A|
|Kathy Gallo-Doyle||VP of Sales||N/A||N/A||N/A|
|Ms. Karina M. Fedasz||Head of Bus. Devel.||N/A||N/A||1973|
|Ms. Katherine Atkinson||Chief Commercial Officer||N/A||N/A||N/A|
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Evofem Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 8.